U.S. markets closed

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
5.20-0.36 (-6.47%)
At close: 4:00PM EDT
5.20 0.00 (0.00%)
After hours: 05:13PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.56
Open5.45
Bid5.15 x 3000
Ask5.44 x 4000
Day's Range5.15 - 5.50
52 Week Range3.45 - 7.45
Volume1,620,695
Avg. Volume1,039,590
Market Cap773.349M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
48% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
    Benzinga

    Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer

    The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway of the Public Health Service Act. The covers for the treatment of metastatic colorectal cancer, in combination with IV fluorouracil-based chemotherapy for first- or second-line therapy and metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatm

  • Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
    Business Wire

    Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

    BRIDGEWATER, N.J., Jun 17, 2021--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Bevacizumab, pursuant to Section 351(k) pathway of the Public Health Service Act, and with a standard review goal date in the second quarter of 2022 according to the BsUFA (Biosimilar User Fee Act).

  • Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
    Business Wire

    Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

    Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that the Food and Drug Administration recently accepted Amneal’s 505(b)(2) New Drug Application for a newly licensed dihydroergotamine (DHE) prefilled syringe autoinjector and the company said it anticipates a decision by the middle of 2022. If approved, Amneal anticipates a commercial launch in the second half of 2022. Amneal plans to commercialize the product solely in the U.S. market.